Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Thumbnail
Fulltext:
221449.pdf
Embargo:
until further notice
Size:
503.4Kb
Format:
PDF
Description:
Publisher’s version
Publication year
2020
Author(s)
Kluck, V.
Jansen, Tim L.Th A.
Janssen, M
Comarniceanu, Antoaneta
Efde, M.N.
Tengesdal, I.W.
Schraa, K.
Cleophas, M.C.P.
Dinarello, C.A.
Joosten, L.A.B.
Source
The Lancet. Rheumatology, 2, 5, (2020), pp. E270-E280
ISSN
DOI
Publication type
Article / Letter to editor
Please use this identifier to cite or link to this item: https://hdl.handle.net/2066/221449   https://hdl.handle.net/2066/221449
Display more details

Upload full text

Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.